Cannabis use and mental health: risks and benefits Wayne HALL, · Eva HOCH, · Valentina LORENZETTI European Archives of Psychiatry and Clinical Neuroscience, february 2019 https://doi.org/10.1007/s00406-019-00986-2 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 In public debates about cannabis policy, two competing claims are often made about how cannabis use may affect mental health. One is that cannabis use by young adults and vulnerable individuals across the lifespan can be a contributory cause of : a cannabis dependence syndrome; schizophreniform psychoses; anxiety and depressive disorders; acute and perhaps chronic cognitive impairment, and structural and functional changes in brain pathways implicated in reward, learning and [...]
Lire la suiteIs cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms ? José Alexandre S. CRIPPA,· Jaime E. C. HALLAK, · Antônio W. ZUARDI · Francisco S. GUIMARAES, · Vitor TUMAS, · Rafael G. dos SANTOS European Archives of Psychiatry and Clinical Neuroscience, 2019, 269(1) DOI : 10.1007/s00406-019-00982-6 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is [...]
Lire la suiteAn Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Kerstin IFFLAND, Franjo GROTENHERMEN Cannabis and Cannabinoid Research, 2017, 2, (1), 139–154. DOI: 10.1089/can.2016.0034 https://www.liebertpub.com/doi/10.1089/can.2016.0034?utm_source=sfmc&utm_medium=email&utm_campaign=CAN%20OA%20Feb%201%202019&d=2/1/2019&mcid=1909944349 Abstract Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy [...]
Lire la suiteThe Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis : no "Strain", no Gain Ethan B. Russo, Frontiers in Plant Science, 2019, Volume 9, Article 1969, 1-8. doi : 10.3389/fpls.2018.01969 The topic of Cannabis curries controversy in every sphere of influence, whether politics, pharmacology, applied therapeutics or even botanical taxonomy. Debate as to the speciation of Cannabis, or a lack thereof, has swirled for more than 250 years. Because all Cannabis types are eminently capable of cross-breeding to produce fertile progeny, it is unlikely that any clear winner will emerge between the “lumpers” vs. “splitters” in this taxonomical debate. This is [...]
Lire la suitehttp://cannabis-med.org/data/pdf/en_2016_01_1.pdf Cannabinoids 2016; 11 (special issue), 1-18 © International Association for Cannabinoid Medicines Review Review on clinical studies with cannabis and cannabinoids 2010-2014 Mikael A. Kowal1, Arno Hazekamp1, Franjo Grotenhermen2 Bedrocan, Veendam, The Netherlands nova-Institut, Chemiepark Knapsack, Industriestraße, D-50354 Hürth, Germany Abstract In 2010 a review by Hazekamp and Grotenhermen covered controlled clinical trials of the years 2006-2009 on cannabis-based medicines, which followed the example of the review by Ben Amar (2006). The current review reports on the more recent clinical data available from 2010- 2014. A systematic search was performed in the scientific database of PubMed, focused on clinical studies that were randomized, (double) blinded, and placebo-controlled. The key words [...]
Lire la suiteDes cannabinoïdes et des hommes. Docteur Rodolphe Ingold, janvier 2018 La semaine dernière, on apprend que deux entrepreneurs sont condamnés à de la prison avec sursis pour avoir mis sur le marché du cannabidiol sous forme fumable dans les cigarettes électroniques. Et en avoir fait la publicité. Ils sont condamnés pour « exercice illicite de la pharmacie ». Sans dire explicitement qu’il s’agissait d’un médicament, ils ont eu l’imprudence de laisser entendre que leur produit pouvait avoir des vertus thérapeutiques. Le point de vue des juges est intéressant. Ils ont évité de poser la question du statut légal du cannabidiol pour s’en prendre à la [...]
Lire la suiteLe cannabis médical en France Dr Bertrand Lebeau, 2014 La situation qui prévaut en France en matière de cannabis médical est profondément paradoxale. D’un côté, les pouvoirs publics font preuve d’une grande pusillanimité et l’on peut dire, sans esprit polémique, que notre pays se situe nettement en queue de peloton en Europe. Ainsi 17 pays européens nous ont précédé avant que la ministre française de la Santé, Marisol Touraine, demande en 2013 à l’instance en charge de ce type de dossier, l’Agence Nationale de Sécurité du Médicament (ANSM), d’examiner la possibilité d’une Autorisation de Mise sur le Marché (AMM) pour le Sativex [...]
Lire la suiteBibliographie CANNABINOIDES et Maladies Neurodégénératives Dr Christian Sueur, GRECC, avril 2019 (2e édition). ALTAMURA C. et al. : Elevation of Plasma 2 –Arachidonoylglycerol Levels in Alzheimer’s Disease Patients as a Potential Protective Mechanism against Neurodegenerativ Decline, Journal of Alzheimer Disease, 2015, 46, 2, 497-506. ASO E., SANCHEZ-PLA A., VEGAS-LOZANO, MALDONADO R., FERRER I. : Cannabis-based medicine reduces multiple pathological process in AβPP/PS1 mice, Journal of Alzheimer’s Disease, 2015, 43, 977-991. ASO E. et al. : Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model, Journal of Alzheimer Disease, 2016, 54, 3, 903-912. BISOGNO T., ODDI S., PICCOLI [...]
Lire la suiteAntidépresseur-like effect induced by Cannabidiol is dependent on brain serotonin levels. A.J. Sales, C. C. Crestani, F. S. Guimaraes, S. R.L. Joca, Progress in Neuropsychopharmacology & Biological Psychiatry, 2018 Aug 30; 86: 255-261. Doi: 10.1016/j.pnpbp.2018.06.002 https://www.ncbi.nlm.nih.gov/pubmed/29885468 PMID : 29885468 Abstract Cannabidiol (CBD) is a compound of Cannabis sativa with relevant therapeutic potential in several neuropsychiatric disorders including depression. CBD treatment has shown significant antidepressant-like effects in different rodent preclinical models. However, the mechanisms involved in CBD-induced antidepressant effects are still poorly understood. Therefore, this work aimed at investigating the participation of serotonin (5-HT) and/or noradrenaline (NA) in CBD-induced antidepressant-like effects in [...]
Lire la suiteCannabis and the Anxiety of Fragmentation - A Systems Approach for Finding an Anxiolytic Cannabis Chemotype, B. S. Kamal, F. Kamal, D. E. Lantela, Frontiers in Neuroscience, 2018, 12, article 730. https://doi.org/10.3389/fnins.2018.00730 Abstract : Cannabis sativa is a medicinal herb with a diverse range of chemotypes that can exert both anxiolytic and anxiogenic effects on humans. Medical cannabis patients receiving organically grown cannabis from a single source were surveyed about the effectiveness of cannabis for treating anxiety. Patients rated cannabis as highly effective overall for treating anxiety with an average score of 8.03 on a Likert scale of 0 to 10 (0 = not effective, [...]
Lire la suite